Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | XIAP | P98170 | 2/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | CCR3 | P51677 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 2/20 | 0.30 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1323963 | 1.00 | MAPK14 (0.32) | MAPK14PTGDR2LMNATSHRCNR1 | |
| SCHEMBL1322829 | 0.93 | MAPK14 (0.33) | MAPK14PTGDR2LMNATSHRPOLB | |
| SCHEMBL1322833 | 0.93 | MAPK14 (0.33) | MAPK14PTGDR2LMNATSHRPOLB | |
| SCHEMBL1322935 | 0.90 | KDM4E (0.36) | MAPK14LMNATSHRPTGER4 | |
| SCHEMBL1322938 | 0.90 | KDM4E (0.36) | MAPK14LMNATSHRPTGER4 | |
| SCHEMBL1322983 | 0.89 | FEN1 (0.39) | MAPK14PTGDR2XIAPCCR3FEN1 | |
| SCHEMBL1322986 | 0.89 | FEN1 (0.39) | MAPK14PTGDR2XIAPCCR3FEN1 | |
| SCHEMBL2211289 | 0.88 | MAPK14 (0.34) | MAPK14CNR1CNR2POLB | |
| SCHEMBL2210663 | 0.88 | MAPK14 (0.34) | MAPK14CNR1CNR2POLB | |
| SCHEMBL1323043 | 0.88 | MAPK14 (0.35) | MAPK14LMNATSHRPOLBXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048571-A1 | Organic Compounds | NOVARTIS AG | 2010-02-25 | — | — | US | claimed |
| EP-2086938-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-08-12 | — | — | EP | claimed |
| WO-2008073306-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-06-19 | — | — | WO | claimed |
| US-8058272-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-15 | — | — | US | disclosed |
| US-8058272-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-15 | — | — | US | disclosed |
| US-8058272-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-15 | — | — | US | disclosed |
| US-20100048571-A1 | Organic Compounds | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20100048571-A1 | Organic Compounds | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20100048571-A1 | Organic Compounds | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048571-A1 | Organic Compounds | XIAP, BAX, MCL1 | MAPK14 2464/4885PTGDR2 4262/4885LMNA 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.